CANTON, NY - St. Lawrence Health Rheumatologist and contributing author of the ACTIV-1 manuscript, Eyal Kedar, MD, was recently recognized by The Journal of the American Medical Association (JAMA).
The organization published the article, Abatacept, Cenicriviroc, or Infliximab for Treatment of Adults Hospitalized With COVID-19 Pneumonia, and posted the full document online.
"The ACTIV-1 trial was important for several reasons,” Dr. Kedar said. “In addition to showing a significant mortality benefit for two immune modulators (infliximab and abatacept) in hospitalized patients with COVID-19, it was also a trial in which St. Lawrence Health, our small rural hospital system, served as an international leader in patient recruitment.
“I would like above all to thank my colleagues from both theinpatient COVID-19 treatment team, and the St. Lawrence Health Department of Clinical and Rural Health Research for their very important contributions to this potentially guideline-changing study," he added.
